Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer
- 27 October 2021
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (4) , e472-e483
Abstract
PURPOSE: Increasing usage of multigene panel testing has identified more patients with pathogenic or likely pathogenic (P or LP) variants in low-moderate penetrance genes or variants of uncertain significance (VUS). Our study evaluates the association between genetic test results and contralateral prophylactic mastectomy (CPM) among patients with breast cancer. METHODS: We conducted a retrospective cohort study among women diagnosed with unilateral stage 0-III breast cancer between 2013 and 2020 who underwent genetic testing. We examined whether genetic test results were associated with CPM using multivariable logistic regression models. RESULTS: Among 707 racially or ethnically diverse women, most had benign or likely benign (B or LB) variants, whereas 12.5% had P or LP and 17.9% had VUS. Racial or ethnic minorities were twice as likely to receive VUS. Patients with P or LP variants had higher CPM rates than VUS or B or LB (64.8% v 25.8% v 25.9%), and highest among women with P or LP variants in high-penetrance genes (74.6%). On multivariable analysis, P or LP compared with B or LB variants were significantly associated with CPM (odds ratio = 4.24; 95% CI, 2.48 to 7.26). CONCLUSION: Women with P or LP variants on genetic testing were over four times more likely to undergo CPM than B or LB. Those with VUS had similar CPM rates as B or LB. Our findings suggest appropriate genetic counseling and communication of cancer risk to multiethnic breast cancer survivors.Keywords
This publication has 30 references indexed in Scilit:
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysisThe Breast, 2014
- After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene PatentsCurrent Genetic Medicine Reports, 2014
- Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk AssessmentJournal of Clinical Oncology, 2014
- Changing Surgical Trends in Young Patients with Early Stage Breast Cancer, 2003 to 2010: A Report from the National Cancer Data BaseJournal of the American College of Surgeons, 2014
- Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersBritish Journal of Cancer, 2011
- International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriersInternational Journal of Cancer, 2008
- Increasing Use of Contralateral Prophylactic Mastectomy for Breast Cancer Patients: A Trend Toward More Aggressive Surgical TreatmentJournal of Clinical Oncology, 2007
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer DiagnosisArchives of Surgery, 2003